OFFICIAL LEGAL TITLE
Homeopathic Drug Product Safety, Quality, and Transparency Act
FREQUENTLY ASKED QUESTIONS
What is the official ID of this bill?
The official print number for this legislation is 119_HR_7050.
Which chamber initiated this legislation?
This legislation was initiated in the House of Representatives.
When did the legislative process begin?
The process officially started on 2026-01-14.
What are the main provisions?
Key points include:
- Homeopathic products are exempt from mandatory FDA premarket approval required for conventional drugs.
- Labels must include a prominent statement that the product's indications for use have not been evaluated by the Food and Drug Administration.
- Manufacturers must adhere to quality and safety standards defined in the Homeopathic Pharmacopoeia of the United States.
- The law limits private lawsuits against manufacturers for false advertising based solely on the lack of clinical trials, provided labeling is compliant.
What is the specific legal status?
The current status is Introduced.
Where can I read the full text of this legislation?
The full official text is available at:
View full text
Who is the primary sponsor?
The primary sponsor is Rep. Sessions, Pete [R-TX-17].
What is the latest detailed status?
The latest detailed status is: Referred to the House Committee on Energy and Commerce.
Is this summary verified?
Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-30.
What is the impact of this bill?
We don't know—that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.